MKI67 and breast carcinoma: Pre-therapy Ki-67 LI (measured in core-biopsies before the initiation of PST) have already been proved to be predictive for pCR in breast cancer patients, but the best predictive cut-off point for the favorable outcome is under debate [18–20].